A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Dec 1, 2026 → Mar 1, 2027
See other at-risk trials from Ruijin Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 1 entry Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion pushed from Dec 1, 2026 to Mar 1, 2027
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 3 of 14 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 18, 2025 to Sep 24, 2025
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Ruijin Hospital
372 trials monitored
See 13 trials at risk
The purpose of this study is to compare the efficacy and safety of firsekibart versus anakinra in patients with AOSD.
Trial Details
NCT Number NCT07191444
Lead Sponsor Ruijin Hospital
Conditions
(from sponsor)		 Still's Disease, Adult-Onset
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov